Ventilator Associated Pneumonia Therapeutics Market
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Prevention
1.2.3 Physiotherapy
1.2.4 Immunity Therapy
1.3 Market by Application
1.3.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Center
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Perspective (2017-2028)
2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Growth Trends by Region
2.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Dynamics
2.3.1 Ventilator Associated Pneumonia (VAP) Therapeutics Industry Trends
2.3.2 Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
2.3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
2.3.4 Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue
3.1.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue
3.4 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio
3.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2021
3.5 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players Head office and Area Served
3.6 Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
3.7 Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type
4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2023-2028)
5 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application
5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
6.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
6.2.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022)
6.2.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028)
6.2.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2017-2028)
6.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
6.3.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022)
6.3.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028)
6.3.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2017-2028)
6.4 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
6.4.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
6.4.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
7.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
7.2.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022)
7.2.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028)
7.2.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2017-2028)
7.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
7.3.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022)
7.3.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028)
7.3.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2017-2028)
7.4 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
7.4.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
7.4.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2017-2028)
8.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2017-2028)
8.4 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
9.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
9.2.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022)
9.2.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028)
9.2.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2017-2028)
9.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
9.3.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022)
9.3.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028)
9.3.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2017-2028)
9.4 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
9.4.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
9.4.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2017-2028)
10.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2017-2028)
10.4 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Achaogen
11.1.1 Achaogen Company Details
11.1.2 Achaogen Business Overview
11.1.3 Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.1.4 Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.1.5 Achaogen Recent Developments
11.2 Adenium Biotech
11.2.1 Adenium Biotech Company Details
11.2.2 Adenium Biotech Business Overview
11.2.3 Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.2.4 Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.2.5 Adenium Biotech Recent Developments
11.3 Aridis Pharmaceuticals
11.3.1 Aridis Pharmaceuticals Company Details
11.3.2 Aridis Pharmaceuticals Business Overview
11.3.3 Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.3.4 Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.3.5 Aridis Pharmaceuticals Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.4.4 AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.4.5 AstraZeneca Recent Developments
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.5.4 Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.5.5 Bayer Recent Developments
11.6 Cardeas Pharma
11.6.1 Cardeas Pharma Company Details
11.6.2 Cardeas Pharma Business Overview
11.6.3 Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.6.4 Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.6.5 Cardeas Pharma Recent Developments
11.7 Destiny Pharma
11.7.1 Destiny Pharma Company Details
11.7.2 Destiny Pharma Business Overview
11.7.3 Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.7.4 Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.7.5 Destiny Pharma Recent Developments
11.8 Dong-A Socio Holdings
11.8.1 Dong-A Socio Holdings Company Details
11.8.2 Dong-A Socio Holdings Business Overview
11.8.3 Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.8.4 Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.8.5 Dong-A Socio Holdings Recent Developments
11.9 Lakewood-Amedex
11.9.1 Lakewood-Amedex Company Details
11.9.2 Lakewood-Amedex Business Overview
11.9.3 Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.9.4 Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.9.5 Lakewood-Amedex Recent Developments
11.10 MedImmune
11.10.1 MedImmune Company Details
11.10.2 MedImmune Business Overview
11.10.3 MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.10.4 MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.10.5 MedImmune Recent Developments
11.11 Meiji Seika Pharma
11.11.1 Meiji Seika Pharma Company Details
11.11.2 Meiji Seika Pharma Business Overview
11.11.3 Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.11.4 Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.11.5 Meiji Seika Pharma Recent Developments
11.12 Merck & Co
11.12.1 Merck & Co Company Details
11.12.2 Merck & Co Business Overview
11.12.3 Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.12.4 Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.12.5 Merck & Co Recent Developments
11.13 Motif Bio
11.13.1 Motif Bio Company Details
11.13.2 Motif Bio Business Overview
11.13.3 Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.13.4 Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.13.5 Motif Bio Recent Developments
11.14 Nabriva Therapeutics
11.14.1 Nabriva Therapeutics Company Details
11.14.2 Nabriva Therapeutics Business Overview
11.14.3 Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.14.4 Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.14.5 Nabriva Therapeutics Recent Developments
11.15 Polyphor
11.15.1 Polyphor Company Details
11.15.2 Polyphor Business Overview
11.15.3 Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.15.4 Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.15.5 Polyphor Recent Developments
11.16 Shionogi & Co
11.16.1 Shionogi & Co Company Details
11.16.2 Shionogi & Co Business Overview
11.16.3 Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.16.4 Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.16.5 Shionogi & Co Recent Developments
11.17 Tetraphase Pharmaceuticals
11.17.1 Tetraphase Pharmaceuticals Company Details
11.17.2 Tetraphase Pharmaceuticals Business Overview
11.17.3 Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.17.4 Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.17.5 Tetraphase Pharmaceuticals Recent Developments
11.18 The Medicines Company
11.18.1 The Medicines Company Company Details
11.18.2 The Medicines Company Business Overview
11.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.18.4 The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.18.5 The Medicines Company Recent Developments
11.19 Theravance Biopharma
11.19.1 Theravance Biopharma Company Details
11.19.2 Theravance Biopharma Business Overview
11.19.3 Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.19.4 Theravance Biopharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.19.5 Theravance Biopharma Recent Developments
11.20 Wockhardt
11.20.1 Wockhardt Company Details
11.20.2 Wockhardt Business Overview
11.20.3 Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.20.4 Wockhardt Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.20.5 Wockhardt Recent Developments
11.21 Zavante Therapeutics
11.21.1 Zavante Therapeutics Company Details
11.21.2 Zavante Therapeutics Business Overview
11.21.3 Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.21.4 Zavante Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.21.5 Zavante Therapeutics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Prevention
Table 3. Key Players of Physiotherapy
Table 4. Key Players of Immunity Therapy
Table 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2017-2022)
Table 9. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2023-2028)
Table 11. Ventilator Associated Pneumonia (VAP) Therapeutics Market Trends
Table 12. Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
Table 13. Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
Table 14. Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
Table 15. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Share by Players (2017-2022)
Table 17. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2021)
Table 18. Ranking of Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
Table 22. Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2017-2022)
Table 26. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2023-2028)
Table 28. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Share by Application (2017-2022)
Table 30. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Share by Application (2023-2028)
Table 32. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 62. Achaogen Company Details
Table 63. Achaogen Business Overview
Table 64. Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 65. Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 66. Achaogen Recent Developments
Table 67. Adenium Biotech Company Details
Table 68. Adenium Biotech Business Overview
Table 69. Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 70. Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 71. Adenium Biotech Recent Developments
Table 72. Aridis Pharmaceuticals Company Details
Table 73. Aridis Pharmaceuticals Business Overview
Table 74. Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 75. Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 76. Aridis Pharmaceuticals Recent Developments
Table 77. AstraZeneca Company Details
Table 78. AstraZeneca Business Overview
Table 79. AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 80. AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 81. AstraZeneca Recent Developments
Table 82. Bayer Company Details
Table 83. Bayer Business Overview
Table 84. Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 85. Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 86. Bayer Recent Developments
Table 87. Cardeas Pharma Company Details
Table 88. Cardeas Pharma Business Overview
Table 89. Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 90. Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 91. Cardeas Pharma Recent Developments
Table 92. Destiny Pharma Company Details
Table 93. Destiny Pharma Business Overview
Table 94. Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 95. Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 96. Destiny Pharma Recent Developments
Table 97. Dong-A Socio Holdings Company Details
Table 98. Dong-A Socio Holdings Business Overview
Table 99. Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 100. Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 101. Dong-A Socio Holdings Recent Developments
Table 102. Lakewood-Amedex Company Details
Table 103. Lakewood-Amedex Business Overview
Table 104. Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 105. Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 106. Lakewood-Amedex Recent Developments
Table 107. MedImmune Company Details
Table 108. MedImmune Business Overview
Table 109. MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 110. MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 111. MedImmune Recent Developments
Table 112. Meiji Seika Pharma Company Details
Table 113. Meiji Seika Pharma Business Overview
Table 114. Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 115. Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 116. Meiji Seika Pharma Recent Developments
Table 117. Merck & Co Company Details
Table 118. Merck & Co Business Overview
Table 119. Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 120. Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 121. Merck & Co Recent Developments
Table 122. Motif Bio Company Details
Table 123. Motif Bio Business Overview
Table 124. Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 125. Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 126. Motif Bio Recent Developments
Table 127. Nabriva Therapeutics Company Details
Table 128. Nabriva Therapeutics Business Overview
Table 129. Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 130. Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 131. Nabriva Therapeutics Recent Developments
Table 132. Polyphor Company Details
Table 133. Polyphor Business Overview
Table 134. Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 135. Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 136. Polyphor Recent Developments
Table 137. Shionogi & Co Company Details
Table 138. Shionogi & Co Business Overview
Table 139. Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 140. Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 141. Shionogi & Co Recent Developments
Table 142. Tetraphase Pharmaceuticals Company Details
Table 143. Tetraphase Pharmaceuticals Business Overview
Table 144. Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 145. Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 146. Tetraphase Pharmaceuticals Recent Developments
Table 147. The Medicines Company Company Details
Table 148. The Medicines Company Business Overview
Table 149. The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 150. The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 151. The Medicines Company Recent Developments
Table 152. Theravance Biopharma Company Details
Table 153. Theravance Biopharma Business Overview
Table 154. Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 155. Theravance Biopharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 156. Theravance Biopharma Recent Developments
Table 157. Wockhardt Company Details
Table 158. Wockhardt Business Overview
Table 159. Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 160. Wockhardt Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 161. Wockhardt Recent Developments
Table 162. Zavante Therapeutics Company Details
Table 163. Zavante Therapeutics Business Overview
Table 164. Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 165. Zavante Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 166. Zavante Therapeutics Recent Developments
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Prevention Features
Figure 3. Physiotherapy Features
Figure 4. Immunity Therapy Features
Figure 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2021 VS 2028
Figure 6. Hospitals Case Studies
Figure 7. Ambulatory Surgical Center Case Studies
Figure 8. Diagnostic Centers Case Studies
Figure 9. Ventilator Associated Pneumonia (VAP) Therapeutics Report Years Considered
Figure 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region: 2021 VS 2028
Figure 13. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players in 2021
Figure 14. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2021
Figure 16. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 17. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 18. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 19. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Country (2017-2028)
Figure 20. United States Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 23. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 24. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 25. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Country (2017-2028)
Figure 26. Germany Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 33. Asia Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 34. Asia Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 35. Asia Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Region (2017-2028)
Figure 36. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 42. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 43. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 44. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 45. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Country (2017-2028)
Figure 46. Mexico Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Middle East and Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 50. Middle East and Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 51. Middle East and Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Country (2017-2028)
Figure 52. Turkey Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Saudi Arabia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. UAE Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Achaogen Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 56. Adenium Biotech Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 57. Aridis Pharmaceuticals Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 58. AstraZeneca Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 59. Bayer Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 60. Cardeas Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 61. Destiny Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 62. Dong-A Socio Holdings Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 63. Lakewood-Amedex Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 64. MedImmune Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 65. Meiji Seika Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 66. Merck & Co Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 67. Motif Bio Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 68. Nabriva Therapeutics Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 69. Polyphor Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 70. Shionogi & Co Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 71. Tetraphase Pharmaceuticals Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 72. The Medicines Company Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 73. Theravance Biopharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 74. Wockhardt Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 75. Zavante Therapeutics Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
Industry Market Size
